Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MGMT | P16455 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038318 | 0.90 | LRRK2 (0.48) | CYP11B1CYP11B2MAPTALDH1A1CYP19A1 | |
| SCHEMBL17323483 | 0.85 | CYP11B1 (0.53) | CYP11B1CYP11B2MAPTALDH1A1CYP19A1 | |
| SCHEMBL14988688 | 0.85 | RAB9A (0.57) | CYP11B1CYP11B2MAPTALDH1A1CYP19A1 | |
| SCHEMBL29447092 | 0.84 | MAPT (0.59) | CYP11B1CYP11B2MAPTALDH1A1RAB9A | |
| SCHEMBL564270 | 0.84 | MAPT (0.59) | CYP11B1CYP11B2MAPTALDH1A1RAB9A | |
| SCHEMBL2038846 | 0.82 | LRRK2 (0.46) | CYP11B1CYP11B2ALDH1A1CYP19A1SMN1; SMN2 | |
| SCHEMBL17630123 | 0.82 | CYP11B1 (0.50) | CYP11B1CYP11B2MAPTCYP19A1RAB9A | |
| SCHEMBL3585058 | 0.80 | MGMT (0.52) | CYP11B1CYP11B2MAPTALDH1A1CYP19A1 | |
| SCHEMBL7900848 | 0.80 | RAB9A (0.51) | CYP11B1CYP11B2MAPTALDH1A1CYP19A1 | |
| SCHEMBL2035674 | 0.79 | KMT2A (0.55) | CYP11B1CYP11B2MAPTALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-7067506-B2 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2005-11-03 | — | — | US | disclosed |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | CYP11B1 3367/4885CYP11B2 3622/4885MAPT 3233/4885 |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | CHEK1, PCNA, CHEK2 | CYP11B1 3367/4885CYP11B2 3622/4885MAPT 3233/4885 |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | CHEK1, PCNA, CHEK2 | CYP11B1 3367/4885CYP11B2 3622/4885MAPT 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.